Aegerion Pharmaceuticals Inc. (AEGR), Cytori Therapeutics Inc (CYTX): Scopia Capital and Sabby Capital Are Bullish on These Stocks

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) continues to feel hedge funds’ bullishness. Not only did Steve Cohen’s Point72 Asset Management disclose an increase in its exposure to the company today, but also Matt Sirovich and Jeremy Mindich’s Scopia Capital did so. According to a Schedule 13G filing, the fund upped its bet by 23.6%, and now owns 5.17 million shares of Common Stock, which account for 17.52% of the Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s shares outstanding. Also today, Hal Mintz’s Sabby Capital more than quadrupled its exposure to Cytori Therapeutics Inc (NASDAQ:CYTX), and now owns 8.39 million shares of Common Stock, which represent 9.99% of the company’s outstanding stock.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is an $865.5 million market cap biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As I mentioned above, two major institutional investors disclosed boosts in their stakes today: Scopia Capital and Point72 Asset Management. Both these purchases came amidst a low prices environment. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) plummeted more than 56% year-to-date, opening an attractive entry point for long-term investors betting on growth. In fact, analysts expect the company to enormously outperform its peers over the mid and long-term, both in terms of EPS growth and stock price.

In addition to these two funds, which are the largest institutional shareholder in the company, amongst those we track, Kevin Kotler’s Broadfin Capital last disclosed having more than doubled its wage on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), to 810,044 shares.

Cytori Therapeutics Inc (NASDAQ:CYTX) is a $39.5 million market cap company engaged in the development of novel treatments for cardiovascular diseases and soft tissue injuries and burns. According to its most recent SEC filing, Sabby Capital added about 6.6 million shares to its holdings in the company, and now owns about 8.39 million shares of Common Stock.

This makes of Hal Mintz’s fund the largest institutional shareholder in the company (amongst those we track) by far. Sabby Capital is trailed by Phill Gross and Robert Atchinson’s Adage Capital Management, which last declared ownership of 124,911 shares of Cytori Therapeutics Inc (NASDAQ:CYTX).

Cytori Therapeutics Inc (NASDAQ:CYTX) has been performing ever worse than Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). The stock lost about 80% year-to-date, opening, once again, a very attractive entry point for long-term investors.

Disclosure: Javier Hasse holds no positions in any stocks or funds mentioned

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.